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Two phases of Hox gene regulation during early Xenopus
development
M.E. Pownall, H.V. Isaacs and J.M.W. Slack
We have shown previously that fibroblast growth factor
(FGF) signalling in posterior regions of the Xenopus
embryo is required for the development of the trunk
and tail via a molecular pathway that includes the
caudal-related gene Xcad3 and the posterior Hox
genes [1]. These results have been contested by the
work of Kroll and Amaya [2], which shows that Xenopus
embryos transgenic for a dominant-negative form of the
FGF receptor (FGF-RI) express posterior Hox genes
normally, leading these authors to suggest that the
FGFs are not required for anteroposterior (A–P)
patterning of the dorsal axis. In order to investigate the
apparent discrepancy between these studies, we have
produced Xenopus embryos transgenic for two
inhibitors of the FGF/Caudal pathway: a kinase-
deficient dominant-negative FGF receptor (XFD) [3];
and a domain-swapped form of Xcad3 (Xcad–EnR) in
which the activation domain of Xcad3 is replaced by the
repression domain of the Drosophila Engrailed protein.
Both of these were introduced as fusions with the
green fluorescent protein (GFP), which allows
identification of non-mosaic transgenic embryos at
early gastrula stages by simply looking for GFP
fluorescence. Analysis of gene expression in embryos
transgenic for these constructs indicated that the
activation of posterior Hox genes during early neurula
stages absolutely requires FGF signalling and
transcriptional activation by Xcad3, while the
maintenance of Hox gene expression in the trunk and
tail during later development is independent of both
FGF and Xcad.
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Results and discussion
Inhibitory mutants of FGF-RI and Xcad3
The initial study of Kroll and Amaya [2] using the trans-
genic Xenopus embryo protocol required a retrospective
identification of transgenic individuals. Here, we use a
technique that allows the identification of live transgenic
embryos in early development through detection of GFP
fusion proteins. This permits the analysis at early stages of
the requirement for zygotic FGF signalling and transcrip-
tional activation by the Caudal-related protein Xcad3 in the
regulation of Hox genes. Figure 1a shows the constructs
used in this study. The dominant-negative FGF receptor
(XFD) [3] was cloned into the CS2+Myc vector [4], which
contains a strong eukaryotic promoter from cytomegalovirus
(CMV) that drives ubiquitous expression from the trans-
gene from the early gastrula stage [2]. In order to detect
cells expressing the inhibitory FGF receptor in living
embryos, GFP was fused in-frame to the carboxyl terminus
of XFD–Myc (XFD–Myc–GFP). Xcad–EnR is an
inhibitory mutant of Xcad3, overexpression of which blocks
Hox gene activation by wild-type Xcad3 [5]. A GFP-tagged
version of Xcad–EnR (Xcad–EnR–GFP) was produced by
fusing GFP to the 3′ end of the homeobox of the original
Xcad–EnR construct in CS2+.
XFD–Myc–GFP and Xcad–EnR–GFP fusion proteins retain
biological activity
Figure 1b shows an RNase protection analysis of animal
caps from embryos injected with eFGF mRNA alone or
co-injected with XFD–Myc–GFP mRNA. Injection of
eFGF mRNA induced strong expression of the mesoder-
mal marker gene Xbra, while co-injection of eFGF and
XFD–Myc–GFP mRNA completely repressed induction
of Xbra [6]. The Myc and GFP tags within the
XFD–Myc–GFP fusion protein did not interfere with its
ability to block FGF signalling and repress the induction
of Xbra by eFGF. Figure 1c shows that whereas injection
of eFGF mRNA alone induced high levels of Hoxa-7
expression, co-injection of mRNA encoding Xcad–EnR or
the fusion protein Xcad–EnR–GFP repressed the induc-
tion of Hoxa-7. In contrast, the levels of Xbra expression
induced by eFGF remained near normal following over-
expression of Xcad–EnR or Xcad–EnR–GFP, demonstrat-
ing that regulation of Xbra expression involves a distinct
molecular pathway to the Xcad3 pathway.
Inhibitory mutants of FGF-RI and Xcad3 tagged with GFP
show appropriate subcellular localisation 
Transgenic embryos were produced by restriction enzyme
mediated integration (REMI) using both XFD–Myc–GFP
and Xcad–EnR–GFP constructs and the subcellular local-
ization of the fusion proteins was examined by confocal
microscopy. Consistent with the previous study [2], the
fluorescence associated with CMV-driven expression from
both transgenes could be detected by mid-gastrula stage
11. The GFP fusion tag allowed the rapid assessment of
whether an embryo was expressing the transgene in all
cells (see Supplementary material, published with this
paper on the internet). For the purposes of this paper, only
embryos that showed non-mosaic expression were
analysed. Figure 2a is a fluorescence image of a gastrula
stage 12 embryo that did not receive a transgene and is
clearly not green. Figure 2b is a confocal image of a sibling
stage 12 embryo transgenic for XFD–Myc–GFP showing
strong peripheral fluorescence in all cells. The fluores-
cence appears absent from some cells only because the
inclusions are outside the confocal plane of focus.
Figure 2c is a confocal image of a stage 12 embryo trans-
genic for Xcad–EnR–GFP showing GFP fluorescence in
the nucleus of the cells as would be expected for a fusion
with the transcription factor Xcad3. 
Transgenic expression of XFD–Myc–GFP and
Xcad–EnR–GFP fusion proteins results in defects in
posterior development
Inhibition of FGF signalling by XFD or inhibition of
Xcad3 activity by Xcad–EnR both resulted in characteris-
tic disruption of posterior development, whereas anterior
development was less affected. The expression of the
XFD–Myc–GFP and Xcad–EnR–GFP transgenes also
resulted in posterior truncations. Figure 2d shows a control
three-day embryo that received a normal sperm, and
Figure 2e shows the phenotype of a sibling embryo trans-
genic for XFD–Myc–GFP. As reported by Kroll and
Amaya [2], the phenotype of the XFD transgenic embryo
was much the same as that resulting from injection of
XFD mRNA [3,7,8] and the XFD fusion with GFP
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Figure 1
(a) Constructs used in this study. The six repeats of the Myc epitope
tag fused to XFD in XFD–Myc are shown in pink; GFP is shown in
green. In Xcad–EnR, the activation domain of Xcad3 was replaced
with the repressor domain of Drosophila Engrailed (blue). To make the
Xcad–EnR–GFP fusion, Xcad–EnR was truncated and GFP (green)
fused after the homeodomain. The numbers indicate the total number
of amino acids in each fusion protein. (b) RNase protection analysis of
a control experiment showing that XFD–Myc–GFP blocks the
activation of Xbra expression in animal caps explanted from embryos
injected with 10 pg eFGF mRNA. RNA (3 µg) from gastrula stage 11
caps was hybridised with probes to Xbra and the loading control
ODC. (c) RNase protection analysis of a control experiment showing
that Xcad–EnR and Xcad–EnR–GFP block activation of Hoxa-7
expression in animal caps explanted from embryos injected with 10 pg
eFGF mRNA. RNA (3 µg) from gastrula stage 12.5 was hybridised
with probes to Hoxa-7, Xbra and ODC.
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Figure 2
Transgenic overexpression of XFD–Myc–GFP and Xcad–EnR–GFP
fusion proteins shows correct subcellular localisation and disrupts
posterior development. (a–c) Fluorescent confocal microscope images
of control and transgenic gastrula stage 12 embryos. (a) An image of
the animal pole region of a non-transgenic control embryo showing faint
autofluorescence from yolk granules. (b) An image of the animal pole
region of an embryo transgenic for XFD–Myc–GFP showing strong
peripheral fluorescence from the membrane-bound receptor–GFP
fusion. Some punctate fluorescence is also visible within intracellular
inclusions in the secretory apparatus. (c) An image of the animal pole
region of an embryo transgenic for Xcad–EnR–GFP showing strong
nuclear fluorescence. (d–f) Control and transgenic embryos at
swimming larva stage 41. (d) Phenotype of a normal control embryo
resulting from non-transgenic nuclear transfer. (e.f) Embryos showing
disruption of posterior development resulting from the transgenic
expression of XFD–Myc–GFP (e) and Xcad–EnR–GFP (f).
resulted in this same phenotype. Figure 2f shows the phe-
notype of a three-day Xcad–EnR–GFP transgenic
embryo, which is similar to that resulting from Xcad–EnR
mRNA injection [5]. 
The use of the GFP tag allows efficient detection of
transgene expression
In a given experiment, only 30–50% of individual embryos
receiving a single transplanted sperm nucleus expressed
the transgene. The inhibitory GFP fusion proteins have
allowed us to identify homogeneous populations of non-
mosaic transgenic embryos or non-transgenic sibling
embryos from shortly after the activation of expression
from the transgene. This has permitted the use of sensi-
tive quantitative techniques for the analysis of effects on
gene expression in pure populations of XFD–Myc–GFP
and Xcad–EnR–GFP transgenic embryos. Figure 3 shows
RNase protection analyses for embryos carrying the
XFD–Myc–GFP transgene. Embryos were collected at
late gastrula (stage 13) and tailbud (stage 25) stages and
separated into transgenic and control populations on the
basis of GFP fluorescence. The accuracy of selection was
confirmed by the detection of strong GFP expression at all
stages examined within the transgenic population and its
complete absence within the control group (Figure 3a).
The efficacy of XFD–Myc–GFP at blocking FGF sig-
nalling in transgenic animals was confirmed by the block
on Xbra expression at the stages examined (Figure 3b).
FGF signalling is required for the initial activation but not
later maintenance of posterior Hox gene expression
Overexpression of eFGF during gastrulation leads to an
up-regulation of ‘posterior’ Hox genes [1]. Two such pos-
terior Hox genes, Hoxa-7 (which is expressed in both ecto-
derm and mesoderm) and Hoxb-9 (which is expressed in
neural tissue), are normally activated by the end of gastru-
lation. The activation of Hoxa-7 expression at the end of
gastrula stages is blocked by overexpression of XFD [1].
The Hox genes are directly involved in the process of A–P
specification and, given the activities and spatial expres-
sion of eFGF, we concluded that FGF signalling was
involved in A–P specification. The initial transgenic
study, however, showed that the expression of the spinal
cord marker Hoxb-9 persists around the open blastopore of
tailbud stage XFD transgenic embryos [2]. The authors
concluded that FGF signalling was not involved in the
regulation of A–P pattern. Experiments in the present
study were designed to resolve the apparent contradiction
in these two data sets [1,2]. 
Figure 3 shows that CMV-driven expression of the
XFD–Myc–GFP transgene greatly repressed the activa-
tion of Hoxa-7 and Hoxb-9 at the late gastrula stage 13. By
tailbud stage 25, however, Hoxa-7 expression levels are
similar to those in non-transgenic siblings (Figure 3a).
Figure 3b shows, consistent with Kroll and Amaya [2], that
by tailbud stage (stage 25), the expression of Hoxb-9 had
also recovered to the level found in controls. As previously
reported [1,2], the recovery of Hox gene expression was in
tissue around the open blastopore (see Supplementary
material). The re-establishment of Hox gene expression
cannot be due to a reduction in expression from the trans-
gene, as the level of GFP expression was maintained and
the expression of Xbra continued to be repressed. Further-
more, the level of Xcad3 expression in XFD–Myc–GFP
transgenic embryos was substantially lower than in control
embryos at all stages, indicating that the recovery of pos-
terior Hox gene expression in late neurula/early tailbud
stages of embryos transgenic for XFD–Myc–GFP is
unlikely to be regulated through Xcad3. These data indi-
cate the existence of other FGF-independent regulators
of posterior Hox gene expression that act during late
neurula and early tailbud stages. The two-phase regula-
tion of posterior Hox gene expression involving an early
FGF-dependent activation phase and a later FGF-inde-
pendent phase resolves the apparent conflict in data sug-
gested by the two studies [1,2]. 
Later expression of posterior Hox genes is independent of
Xcad3
Overexpression of Xcad–EnR resulted in a dramatic inhi-
bition of posterior development and blocked the activa-
tion of the same Hox genes that are activated by Xcad3 [5].
Figure 4 shows RNase protection analysis of embryos
transgenic for Xcad–EnR–GFP. Again, the accuracy of
transgenic versus non-transgenic selection was confirmed
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Figure 3
RNase protection analyses showing gene expression in embryos
carrying the XFD–Myc–GFP transgene at late gastrula stage 13 and
tailbud stage 25. (a) Expression of GFP, Hoxa-7 and ODC in
transgenic and non-transgenic siblings. (b) Expression of Hoxb-9,
Xcad3, Xbra and ODC in transgenic and non-transgenic siblings. RNA
(3 µg) from each group was hybridised with relevant probes.
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by the presence of high-level non-mosaic GFP expression
in the transgenic group. As with XFD–Myc–GFP trans-
genic embryos, Hoxa-7 expression was also repressed
during neurula stages in Xcad–EnR–GFP transgenic
embryos (Figure 4). By tailbud stages, however, Hoxa-7
expression recovered to levels similar to control levels,
indicating that although Xcad–EnR–GFP can repress
Hoxa-7 expression during neurula stages, it is not able to
do so during tailbud stages. This might indicate that
binding of Xcad3 to its normal targets, such as regulatory
regions in the Hox genes, may require cofactors that are
present in gastrula and neurula stages but not during later
neurula and tailbud stages. In any case, not only is this
later phase of Hox gene regulation FGF independent, but
it is also Xcad3 independent.
In conclusion, it is widely accepted that A–P patterning of
the amphibian embryo occurs during gastrula stages as the
dorsal mesoderm comes to underlie the neural plate. The
advantages of using the tagged XFD–Myc–GFP and
Xcad–EnR–GFP fusions in Xenopus embryos have allowed
us to demonstrate that there is an initial phase in which the
activation of posterior Hox gene expression is dependent
on FGF signalling and Xcad3 activity. This is consistent
with previous studies showing that FGF has the biological
activity of a posteriorising or transforming factor [9–11].
During early tailbud stages, however, there is a second
phase of Hox gene expression that is independent of FGF
and Xcad3. These data indicate that the signals involved in
the normal activation of posterior Hox genes during early
neurula stages are different from those regulating the
maintenance of their expression during tailbud stages. 
Materials and methods
Construction of fusion proteins
The XFD used is the 64TXFD from Kroll and Amaya [2] and nucleotides
1–1215 were PCR cloned into the CS2+Myc plasmid [4].
XFD–Myc–GFP was made by blunt cloning BamHI-excised and filled
GFP (the S64T variant from R. Tsien was used in this construct) into the
Stu site of CS2–XFD–Myc. The CS2–Xcad3 plasmid used was as
described in [1]. The Xcad3 repressor construct (CS2–Xcad–EnR) was
made by cloning the sequence encoding amino acids 121–275 of Xcad3
into CS2–ENG-N (from D. Kessler). GFP2 was fused in-frame to the car-
boxyl end of Xcad–EnR at the BsrGI site, 3′ to the homeobox (GFP2 from
E. Amaya, modified to be brighter by J. Haseloff and J. Pines).
Transgenic Xenopus
The technique used to generate transgenic embryos is as in [2].
RNase protection analysis
RNA was prepared and analysed by RNase protection as described in
[1]. Ornithine decarboxylase (ODC) was the loading control. The other
probes used, Xbra [6], Hoxb-9 [1], Hoxa-7 and Xcad3, were as
described in [1]. The GFP is a subclone of GFP2 (from E. Amaya) in
Bluescript (Stratagene).
Supplementary material
Supplementary material published with this article on the internet
includes a densiometric analysis of the gene expression studies from
the work and photographic images of GFP fluorescence in transgenic
specimens as well as in situ hybridisation of Hox gene expression.
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Figure 4
RNase protection analysis showing GFP and Hoxa-7 expression in
embryos carrying the Xcad–EnR–GFP transgene at late gastrula
stage 13, late neurula stage 18 and tailbud stage 25. RNA (3 µg) from
each group was hybridised with GFP, Hoxa-7 and ODC probes.
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S1Supplementary material
Table S1
Densitometric analysis of gene expression in XFD–Myc–GFP transgenic embryos.
Probe Stage 13 Stage 13 transgenic Stage 13 ratio Stage 25 control Stage 25 transgenic Stage 25 ratio
control XFD–Myc–GFP Control:T.G XFD–Myc–GFP Control:T.G
Xbra 100% 4% 25:1 18% 2% 9:1
Hoxa-7 100% 20% 5:1 74% 49% 1.5:1
Hoxb-9 100% 19% 5:1 164% 205% 1:0.8
Densitometric analysis was carried out using the ‘NIH Image’ program
on images from pre-flashed autoradiographs scanned using a UMAX
flatbed scanner. Values are expressed as percentages of stage 13
levels normalized to the ODC expression. These data show that at late
gastrula stage 13, expression of Xbra, Hoxa-7 and Hoxb-9 is greatly
reduced in embryos carrying the XFD–Myc–GFP transgene, indicating
a requirement for FGF signalling for the expression of these genes in
the gastrula. At tailbud stage 25, the level of Xbra expression remains
highly repressed indicating the continued inhibition of the FGF
signalling pathway. The expression levels of the posterior Hox genes
Hoxa-7 and Hoxb-9, however, have returned to near that in control
siblings, demonstrating a second, FGF-independent phase of posterior
Hox gene expression.
Figure S1
Uniform expression of the XFD–Myc–GFP transgene in a tailbud stage
25 embryo. Fluorescence image showing the ubiquitous expression of
the GFP-tagged dominant-negative FGF receptor protein
(XFD–Myc–GFP). Anterior is to the left. 
Figure S2
The recovery of Hoxa-7 expression in a tailbud stage XFD–Myc–GFP
transgenic embryo. The top embryo is at tailbud stage 27 and shows
normal Hoxa-7 expression in the trunk and developing tail forming
regions. The bottom stage 27 embryo is transgenic for XFD–Myc–GFP
and shows the recovery of Hoxa-7 expression around the margins of
the open blastopore (bp). Anterior is to the left.
